National Jewish Center for Immunology and Respiratory Medicine

National Jewish Medical and Research Center

National Jewish Health

Philippa Marrack

John W Kappler

Brian L Kotzin

Xavier Paliard

Brian C Schaefer

Michael Jordan

Youngwon Choi

Yongwon Choi

Anatoly Rubtsov

Disclosed are methods for evaluating the activation of Bcl10 in a cell in response to a putative stimulus, as well as methods for evaluating or identifying a regulatory compound which regulates activation of Bcl10-mediated signal transduction. These methods utilize the discovery of the activation-dependent formation in a cell of Bcl10 aggregates in a cell.

Method to identify regulators of cellular activation using Bcl10

Disclosed are a composition and method to treat or prevent antibody-induced anemia and particularly, autoimmune hemolytic anemia. The composition comprises a bisphosphonate and a pharmaceutically acceptable carrier. In a preferred embodiment, the composition comprises clodronate and a liposome carrier.

Composition and method for treating autoimmune hemolytic anemia

The present invention relates to a product and process for regulating the activity of T cells using major histocompatibility complexes (MHC) stably linked to antigenic peptides. Disclosed is an antigenic peptide covalently linked to a major histocompatibility complex (MHC) protein by a novel linker, thereby enabling the formation of a stable peptide-MHC complex, alone or in combination with additional MHC protein chains, capable of being recognized by a T cell receptor (TCR). Also disclosed is a nucleic molecule having a sequence encoding a Peptide-L-MHC molecule comprising an antigenic peptide joined by a linker to an MHC segment. The invention is additionally directed to formulations comprising an antigenic peptide joined by a linker to an MHC segment anchored in a lipid-containing substrate. Pharmaceutical reagents are also disclosed which contain an antigenic peptide joined by a linker to an MHC segment combined with a suitable carrier that is capable of presenting the Peptide-L-MHC molecule so that it is capable of being recognized by a T cell receptor.

Product and process for T cell regulation

The invention relates to a method for identifying T cell populations involved in autoimmune diseases. This involves determining levels of a V.beta. element in a body fluid sample of a patient and comparing this to normal levels. Variation from normal levels is indicative of an autoimmune disease. The invention also involves assaying T cell subpopulations in a sample to determine clonality of .beta. chains. Clonality can also be used to diagnose autoimmune disorders.

Method for identifying T cells involved in autoimmune disease

Recombinant DNA vectors which express chimeric T cell receptors are disclosed. These chimeric T cell receptors contain one human element, and the rest of the elements are all of the same, non-human animal species, such as a mouse. Of particular interest are chimeras where the human element is V.alpha. or V.beta.. The vectors are used to transfect cells which derive from the same non-human animal species as the non-human animal species of the chimera, and the resulting transfectants are used to produce monoclonal antibodies against the human element of the chimera.

Process for producing monoclonal antibodies against human T cell

The invention teaches a method for determining levels of T-cell surface antigens in humans, specifically, V.beta. molecules. Measurement of such levels allows for diagnosis of pathological conditions, such as infections, where changes in these levels are indicative of a superantigen initiated pathological condition.

Growing community of inventors

Denver, CO, United States of America

Philippa Marrack